Table 1 Correlation between clinicopathological findings and CD133 status
From: Significance of CD133 expression in esophageal squamous cell carcinoma
| Â | Â | Total (%) | CD133 expression | Â | P |
|---|---|---|---|---|---|
| Â | Â | Â | Positive | Negative | Â |
| Â | Â | Â | n= 38 (44.2%) | n= 48 (55.8%) | Â |
Age (years) | Mean ± SD | 63.9 ± 9.4 | 64.8 ± 10.9 | 63.2 ± 8.0 | 0.45 |
|  | (Range) | (37–81) | (37–9) | (44–81) | |
Sex | Male | 73 (84.9) | 32 (84.2) | 41 (85.4) | 0.88 |
Female | 13 (15.1) | 6 (15.8) | 7 (14.9) | ||
Smoking | Absent | 13 (15.1) | 8 (21.1) | 5 (10.4) | 0.17 |
Present | 73 (84.9) | 30 (79.0) | 43 (89.6) | ||
Location | Cervix | 5 (5.8) | 3 (7.9) | 2 (4.2) | 0.59 |
Upper | 5 (5.8) | 1 (2.6) | 4 (8.3) | ||
Middle | 35 (40.7) | 17 (44.7) | 18 (37.5) | ||
Lower | 41 (47.7) | 17 (44.7) | 24 (50.0) | ||
Histological type | Well | 17 (19.8) | 9 (23.7) | 8 (16.7) | 0.68 |
Moderate | 56 (65.1) | 23 (60.5) | 33 (68.8) | ||
Poor | 13 (15.1) | 6 (15.8) | 7 (14.6) | ||
pT | pT1 | 28 (32.6) | 19 (50.0) | 9 (18.8) | 0.017 |
pT2 | 9 (10.5) | 3 (7.9) | 6 (12.5) | ||
pT3 | 46 (53.5) | 15 (39.5) | 31 (64.6) | ||
pT4 | 3 (3.5) | 1 (2.6) | 2 (4.2) | ||
pN | pN0 | 36 (41.9) | 19 (50.0) | 17 (35.4) | 0.17 |
pN1-3 | 50 (58.1) | 19 (50.0) | 31 (64.6) | ||
pM | pM0 | 81 (94.2) | 35 (92.1) | 46 (95.8) | 0.65 |
pM1 (LYM) | 5 (5.8) | 3 (7.9) | 2 (4.2) | ||
pStage | pStageI | 20 (23.3) | 14 (36.8) | 6 (12.5) | 0.035 |
pStageII | 28 (32.6) | 9 (23.7) | 19 (39.6) | ||
pStageIII | 33 (38.4) | 12 (31.6) | 21 (43.8) | ||
pStageIV | 5 (5.8) | 3 (7.9) | 2 (4.2) | ||
Lymphatic invasion | Negative | 34 (39.5) | 13 (34.2) | 21 (43.8) | 0.37 |
Positive | 52 (60.5) | 25 (65.8) | 27 (56.3) | ||
Venous invasion | Negative | 31 (36.1) | 11 (29.0) | 20 (41.7) | 0.22 |
| Â | Positive | 55 (64.0) | 27 (71.1) | 28 (58.3) | Â |